Back to News
Market Impact: 0.25

BDX Quantitative Stock Analysis

Company FundamentalsAnalyst InsightsCorporate EarningsHealthcare & BiotechInvestor Sentiment & Positioning
BDX Quantitative Stock Analysis

Validea's guru fundamental report indicates Becton Dickinson (BDX), a large-cap medical equipment firm, received its highest rating (54%) using the Peter Lynch-inspired P/E/Growth Investor model. While this strategy seeks reasonable price-to-earnings growth and strong balance sheets, BDX's 54% score falls below the 80% threshold for 'some interest,' reflecting mixed fundamental performance including passes on P/E/Growth and debt/equity but failures on sales/P/E and EPS growth rate.

Analysis

According to Validea's fundamental report, Becton Dickinson and Co. (BDX) receives a lukewarm assessment based on the Peter Lynch P/E/Growth investment model, scoring just 54%. This is significantly below the 80% threshold that would typically indicate strategic interest. The analysis reveals a mixed fundamental picture: BDX passes on its P/E/Growth ratio, inventory-to-sales management, and total debt-to-equity ratio, suggesting a reasonable valuation and a healthy balance sheet. However, these strengths are offset by critical failures in its EPS growth rate and sales-to-P/E ratio, two metrics central to a growth-oriented thesis. Furthermore, the company's free cash flow and net cash position were deemed neutral, providing no strong positive or negative signal. The overall moderately negative sentiment score of -0.4 reflects that, despite its balance sheet stability, BDX's lack of demonstrated earnings growth makes it an uncompelling candidate under this specific quantitative framework.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request Demo

More News